Skip navigation

Navigate Country-Specific Regulations and Reimbursement Models ● Optimise Stakeholder Collaboration ● Utilise Real-World Data Collection

May 21-22, 2019
  • Amsterdam, The Netherlands

At CBI’s 4th Annual Managed Access Programmes and Accelerated Pathways, join dedicated peers to address the nuances and complexities of designing and implementing early access programmes to accelerate access to lifesaving therapies. Convene with key stakeholders for an in-depth and meaningful conversation on the implications, prevailing policies and current industry approaches of managed access programs. Don’t miss the opportunity to share best practices around providing investigational, pre-launch or end-of-lifecycle drugs to patients for treatment purposes around the world.

Join Stakeholders to Collaborate
on Action Steps To:

  • Expanded Access and the Optimising the Patient Journey
  • Enhance Collaboration amongst Patient Advocacy Groups,
    Payers and Manufacturers
  • Operationalise a Successful Managed Access Programmes
  • Compassion vs. Viability — Ethical Implications to Consider when Carrying Out Managed Access Programmes
  • Revolutionise Managed Access Programmes for Better
    Patient Centricity
  • Navigate Regulatory Landscape on a Global Level
  • Open Discussion — Enhance Collaboration between
    Patient Advocacy Groups and Manufacturers
  • Cross-Collaboration with Local Partnersto Run a
    Managed Access Programme
NEW FOR 2019! Choose Between Two In-Conference Breakouts

A. Real-World Data —
Supporting Product Effectiveness, Safety and Value

B. From Clinical to Commercial —
Accelerating Access to Orphan Drugs for Rare Diseases

Previous Attendee Acclaim:

GREAT INSIGHTS from a variety of perspectives including the patients, regulators and manufacturers, who all ADDRESSED REAL ISSUES.

Vice President, AmerisourceBergen

I learned a tremendous amount and have many NEW PERSPECTIVES to bring back to my own work. The conference gave me NEW INSIGHTS to consider related to reimbursement and real-world data generation when planning Expanded Access/Pre-Approval Access programs.

Early Patient Access Program Lead, Bristol-Myers Squibb

Very informative conference.
GREAT SPEAKERS and collaborative meeting!

Associate Director, Amicus Therapeutics